Lutathera

Lutathera (lutetium (177Lu) oxodotreotide) is a cancer medicine for treating tumours in the gut known as gastroenteropancreatic neuroendocrine tumours (GEP‑NETs). It is a radiopharmaceutical (a medicine that emits a small amount of radioactivity). Lutathera is used to treat GEP-NETs that cannot be removed by surgery, have spread to other parts of the body or are not responding to treatment. Lutathera was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 31 January 2008.

If you are a SAM Nordic customer and wish to order Lutathera, please download the order form, complete it and send to order@samnordic.se

Download Lutathera Order Form here

Delivered to
Questions about expiration date & durability?

Description

Lutathera is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP‑NETs) in adults.


The mechanism of action

Lutathera (lutetium 177Lu oxodotreotide) is a radiolabeled somatostatin analog. Lutathera binds to somatostatin receptors with highest affinity for subtype 2 receptors (SSRT2). Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumors, the compound is internalized.

The beta emission from Lu 177 induces cellular damage by formation of free radicals in somatostatin receptor-positive cells and in neighboring cells.

Follow the link to watch the mechanism of action for Lutathera


Efficacy

Lutathera can help slow down the worsening of GEP‑NETs. In a main study of 229 patients with GEP‑NETs that contained somatostatin receptors, patients given Lutathera lived for an average of 28 months without their disease getting worse. This compares with around nine months for patients treated with octreotide, a medicine already approved for treating the condition.

Only a minority of patients with GEP‑NETs can be cured with surgery and at the time of diagnosis the tumours would have spread in most patients. Lutathera can help slow the worsening of the condition and its side effects are considered manageable.

Read more about Lutathera in the summary of the European Medicines Agency’s public assessment report (EPAR)


Side effects with Lutathera

The most common side effects seen with Lutathera treatment are nausea and vomiting, which occurred at the start of the infusions in around half of patients and may be related to the amino acid infusion.


Information for HCP

Follow the link to find your local SmPC

Denmark https://www.ema.europa.eu/en/documents/product-information/lutathera-epar-product-information_da.pdf

Estonia https://www.ema.europa.eu/en/documents/product-information/lutathera-epar-product-information_et.pdf

Finland https://www.ema.europa.eu/en/documents/product-information/lutathera-epar-product-information_fi.pdf

Norway https://www.ema.europa.eu/en/documents/product-information/lutathera-epar-product-information_no.pdf

Sweden https://www.ema.europa.eu/en/documents/product-information/lutathera-epar-product-information_sv.pdf


Additional Information about Lutathera

For additional information regarding Lutathera or gastroenteropancreatic neuroendocrine tumors, please visit http://www.adacap.com/


Practical information

Please contact the SAM Nordic customer service departement if you hav e any further questions.
+46-8-720 58 22
info@samnordic.se

Lutathera is manufactured by Advanced Accelerator Applications (AAA) and is distributed in the Nordic and Baltic region by SAM Nordic.

Download brochures below